The CBO says Trump’s proposed NIH funding cuts and longer FDA review times could significantly reduce the number of new drugs entering the U.S. market.
The CBO says Trump’s proposed NIH funding cuts and longer FDA review times could significantly reduce the number of new drugs entering the U.S. market.
Copyright © Louis Velazquez. All Rights Reserved.